PL374673A1 - Izolacja i identyfikacja komórek T - Google Patents

Izolacja i identyfikacja komórek T

Info

Publication number
PL374673A1
PL374673A1 PL03374673A PL37467303A PL374673A1 PL 374673 A1 PL374673 A1 PL 374673A1 PL 03374673 A PL03374673 A PL 03374673A PL 37467303 A PL37467303 A PL 37467303A PL 374673 A1 PL374673 A1 PL 374673A1
Authority
PL
Poland
Prior art keywords
isolation
cells
identification
Prior art date
Application number
PL03374673A
Other languages
English (en)
Other versions
PL214283B1 (pl
Inventor
Jingwu Z. Zhang
Original Assignee
Baylor College Of Medicine
Opexa Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine, Opexa Pharmaceuticals Inc. filed Critical Baylor College Of Medicine
Publication of PL374673A1 publication Critical patent/PL374673A1/pl
Publication of PL214283B1 publication Critical patent/PL214283B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Mycology (AREA)
PL374673A 2002-08-08 2003-08-06 Sposób izolacji komórek T, sposób wytwarzania autologicznej szczepionki komórek T, autologiczna szczepionka komórek T, zastosowanie autologicznej szczepionki komórek T PL214283B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40252102P 2002-08-08 2002-08-08

Publications (2)

Publication Number Publication Date
PL374673A1 true PL374673A1 (pl) 2005-10-31
PL214283B1 PL214283B1 (pl) 2013-07-31

Family

ID=31715870

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374673A PL214283B1 (pl) 2002-08-08 2003-08-06 Sposób izolacji komórek T, sposób wytwarzania autologicznej szczepionki komórek T, autologiczna szczepionka komórek T, zastosowanie autologicznej szczepionki komórek T

Country Status (18)

Country Link
US (2) US7695713B2 (pl)
EP (2) EP1546719B1 (pl)
JP (2) JP4705371B2 (pl)
KR (1) KR100795840B1 (pl)
CN (1) CN100567987C (pl)
AU (1) AU2003258090B2 (pl)
BR (1) BRPI0305769A8 (pl)
CA (2) CA2759572A1 (pl)
ES (2) ES2537951T3 (pl)
IL (1) IL166332A (pl)
MX (1) MXPA05001044A (pl)
NO (2) NO338881B1 (pl)
NZ (1) NZ537816A (pl)
PL (1) PL214283B1 (pl)
PT (2) PT2363710E (pl)
RU (1) RU2327487C2 (pl)
WO (1) WO2004015070A2 (pl)
ZA (1) ZA200500985B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
CA2759572A1 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
CN101287831B (zh) * 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
PT1989544E (pt) * 2006-03-02 2011-09-26 Antitope Ltd Ensaios com células t
ES2686593T3 (es) 2006-05-31 2018-10-18 The Regents Of The University Of California Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
GB0707933D0 (en) * 2007-04-24 2007-05-30 Apitope Technology Bristol Ltd Disease markers
US20090062237A1 (en) * 2007-06-15 2009-03-05 Mayo Foundation For Medical Education And Research Evaluating immune competence
EP2358383A4 (en) * 2008-11-21 2011-11-23 Univ Miami HIV / SIV VACCINES FOR THE MANUFACTURE OF SLEEPAGE AND SYSTEM IMMUNITY
US8497071B2 (en) 2009-06-29 2013-07-30 California Institute Of Technology Isolation of unknown rearranged T-cell receptors from single cells
WO2011080349A1 (en) * 2010-01-04 2011-07-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Detection method of anti-myelin autoreactive t-cells and diagnostic method of autoimmune disease
US20130071860A1 (en) * 2010-02-24 2013-03-21 Matthew B. Hale Methods for autoimmune disease diagnosis, prognosis, and treatment`
DE102011050550A1 (de) * 2011-05-20 2012-11-22 Wolfgang Göhde Verfahren und Anordnung zur Quantifizierung von Untergruppen aus einer Mischpopulation von Zellen
EP2726879B1 (en) 2011-07-01 2022-10-19 Beckman Coulter, Inc. Requlatory t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
JP2014528001A (ja) * 2011-09-28 2014-10-23 シービー バイオテクノロジーズ インコーポレイテッド アームｐｃｒおよび高処理シーケンシングを用いた抗原特異的適応免疫応答の同定法
FR2992427A1 (fr) * 2012-06-20 2013-12-27 Assist Publ Hopitaux De Paris Methode de pronostic d'un lymphome et kit pour sa mise en oeuvre
AU2013280416B2 (en) * 2012-06-27 2017-06-15 Rutgers, The State University Of New Jersey Rapid assays for T-cell activation by RNA measurements using flow cytometry
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
JP6508873B2 (ja) * 2014-01-20 2019-05-08 国立大学法人富山大学 抗原特異的ｔ細胞受容体の取得方法
AU2016315752B2 (en) 2015-08-31 2021-08-05 Cedars-Sinai Medical Center Novel blood cell biomarker for late onset Alzheimer's disease
US10731133B2 (en) * 2015-09-11 2020-08-04 Astellas Pharma Inc. Method for producing renal progenitor cells
EP3465203B1 (en) 2016-05-25 2026-03-18 The Council of the Queensland Institute of Medical Research Methods of immunotherapy
AU2017290119A1 (en) * 2016-06-28 2019-01-24 Geneius Biotechnology, Inc. T cell compositions for immunotherapy
CA3050299A1 (en) * 2017-01-20 2018-07-26 Atara Biotherapeutics, Inc. Methods of treating multiple sclerosis using autologous t cells
JP7193054B2 (ja) * 2017-06-14 2022-12-20 シンガポール ヘルス サービシズ ピーティーイー． リミテッド 自己免疫疾患の臨床転帰を評価するための方法及びキット
EP3731860A1 (en) 2017-12-29 2020-11-04 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Compositions and methods for treating autoimmune disease
PL445027A1 (pl) * 2023-05-29 2024-12-02 Uniwersytet Medyczny w Łodzi Sposób diagnozowania stwardnienia rozsianego in vitro

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
US4677061A (en) * 1984-10-19 1987-06-30 Genetic Systems Corporation T-cell lymphocyte subset monitoring of immunologic disease
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4902680A (en) 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US4898856A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
US4898857A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Treating control nervous system diseases
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1296622C (en) * 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5039660A (en) * 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US4902857A (en) * 1988-12-27 1990-02-20 American Telephone And Telegraph Company, At&T Bell Laboratories Polymer interconnect structure
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5861164A (en) * 1989-03-21 1999-01-19 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) * 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6007815A (en) * 1989-03-21 1999-12-28 The Immune Response Corporation Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
IL165071A (en) 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
WO1992001044A1 (en) 1990-07-06 1992-01-23 Allergene, Inc. Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5545716A (en) * 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
EP0688223A4 (en) * 1993-03-12 1998-05-13 Cellcor Inc -i (IN VITRO) 'ASSAY' FOR MEASURING THE DEGREE OF ACTIVATION OF IMMUNE CELLS
US5494899A (en) * 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
AU6376194A (en) 1993-05-14 1994-12-12 Dr. L. Willems-Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US5956058A (en) * 1993-11-05 1999-09-21 Seiko Epson Corporation Ink jet print head with improved spacer made from silicon single-crystal substrate
US5552300A (en) 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6410518B1 (en) * 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
US5723503A (en) 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US6033661A (en) * 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US6096314A (en) * 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
SE9502921D0 (sv) * 1995-08-23 1995-08-23 Astra Ab New compounds
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5849886A (en) * 1996-07-10 1998-12-15 Oy Aboatech Ab Extraction of myelin basic protein
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6054292A (en) * 1997-07-18 2000-04-25 Incyte Pharmaceuticals, Inc. T-cell receptor protein
US20020009448A1 (en) * 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20020001841A1 (en) * 1998-06-26 2002-01-03 Keld Kaltoft Continuous t-cell lines
US6114129A (en) * 1998-06-26 2000-09-05 Biomira, Inc. Methods of detecting T-cell activation and treating disorders associated with T-cell dysfunction
AU5906099A (en) 1998-09-04 2000-03-27 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease
CA2362099C (en) * 1999-02-23 2014-05-13 Baylor College Of Medicine T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection
US6187750B1 (en) * 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
WO2001031021A1 (en) * 1999-10-28 2001-05-03 Universite De Geneve Multiple sclerosis-related superantigen
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
MXPA03001569A (es) 2000-08-22 2004-12-13 Baylor College Medicine Secuencia de vbeta-dbeta-jbeta del receptor de celula y metodos para su deteccion.
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US20030153073A1 (en) * 2001-11-07 2003-08-14 Paul Rogers Expansion of T cells in vitro and expanded T cell populations
US20050181459A1 (en) * 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
CA2759572A1 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells

Also Published As

Publication number Publication date
EP1546719A2 (en) 2005-06-29
IL166332A (en) 2010-12-30
PL214283B1 (pl) 2013-07-31
BR0305769A (pt) 2005-06-28
AU2003258090B2 (en) 2010-07-22
CN1675542A (zh) 2005-09-28
PT1546719E (pt) 2015-07-02
BRPI0305769A8 (pt) 2017-09-12
CA2759572A1 (en) 2004-02-19
ES2537951T3 (es) 2015-06-16
KR20050034724A (ko) 2005-04-14
WO2004015070A3 (en) 2004-11-11
ZA200500985B (en) 2006-02-22
US7695713B2 (en) 2010-04-13
AU2003258090A1 (en) 2004-02-25
NO20150482L (no) 2005-03-07
WO2004015070A2 (en) 2004-02-19
ES2545736T3 (es) 2015-09-15
EP1546719B1 (en) 2015-04-01
IL166332A0 (en) 2006-01-16
JP2005535328A (ja) 2005-11-24
HK1082520A1 (zh) 2006-06-09
CA2492848C (en) 2012-01-24
US20100239548A1 (en) 2010-09-23
KR100795840B1 (ko) 2008-01-17
JP4705371B2 (ja) 2011-06-22
RU2327487C2 (ru) 2008-06-27
NO338881B1 (no) 2016-10-31
US20060105336A1 (en) 2006-05-18
NO20050447L (no) 2005-03-07
JP2010178759A (ja) 2010-08-19
EP2363710A1 (en) 2011-09-07
EP1546719A4 (en) 2007-01-03
RU2005106842A (ru) 2005-10-10
MXPA05001044A (es) 2005-06-22
CN100567987C (zh) 2009-12-09
EP2363710B1 (en) 2015-07-01
PT2363710E (pt) 2015-10-01
NZ537816A (en) 2007-06-29
CA2492848A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
IL166332A0 (en) Isolation and identification of t cells
AU2003273542A8 (en) Methods of identifying and isolating stem cells and cancer stem cells
AU2003239159A8 (en) Placental derived stem cells and uses thereof
AU2003217337A8 (en) High-throughput cell identification and isolation method and apparatus
PL375691A1 (pl) Imidazolopirydyny i sposoby ich wytwarzania i stosowania
AU7813401A (en) Isolation and use of solid tumor stem cells
AU2003288902A8 (en) Microcapsules and methods of use
EP1474445A4 (en) ADIPONECTIN GLYCO-ISOFORMS, AND USES THEREOF
AU2003300421A8 (en) Rfid device and method of forming
AU2003294246A8 (en) Circulating stem cells and uses related thereto
EP1687411A4 (en) IDENTIFICATION AND ISOLATION OF HEMATOPOIETIC STEM CELLS
GB2427616B (en) Stem cells
PL375355A1 (pl) Nowe lipazy i ich zastosowanie
IL166370A0 (en) Embryonic stem cell markers and uses thereof
AU2003235577A8 (en) Identification of small ruminants
EP1697715A4 (en) IDENTIFICATION, ISOLATION AND ELIMINATION OF CANCER STEM CELLS
AU2003299914A8 (en) Isolation and identification of cross-reactive t cells
AU2003285686A8 (en) Glycoisoforms of adiponectin and uses thereof
GB0102717D0 (en) Cells and uses therefor
AU2002352696A8 (en) Cell substrates and methods of use thereof
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003217743A8 (en) Magnetic immobilization of cells
AU2003219429A1 (en) Method for the identification and isolation of stem cells from a human tissue
AU2003304115A8 (en) Dinoflagellate karlotoxins, methods of isolation and uses thereof
AU2003267790A8 (en) Lipase inhibitors and uses thereof